POOLBEG PHARMA PLC
AI-led biopharma developing drugs for high-need diseases like CRS and metabolic disorders.
POLB | IL
Overview
Corporate Details
- ISIN(s):
- GB00BKPG7Z60
- LEI:
- 213800UZ8WJLWYHBFL52
- Country:
- United Kingdom
- Address:
- QUEEN MARY BIOENTERPRISES INNOVATION CENTRE, E1 2AX LONDON
- Website:
- https://poolbegpharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company that acquires, develops, and commercializes innovative medicines for diseases with high unmet medical needs. The company utilizes a proprietary, AI-led discovery platform that leverages over 20 years of human challenge trial data to identify novel drug targets and treatments. This AI-driven approach aims to accelerate target identification, reduce costs, and increase the probability of clinical success. Key programmes in its pipeline target conditions such as cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic disorders, including an oral encapsulated GLP-1 programme for obesity.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-29 08:00 |
Earnings Release
Interim Results for the six months to 30 June 2025
|
English | 155.8 KB | ||
| 2025-07-01 17:24 |
Major Shareholding Notification
Notification of Major Holdings
|
English | 43.8 KB | ||
| 2025-06-23 15:57 |
Post-Annual General Meeting Information
Results of GM and AGM Meetings
|
English | 16.0 KB | ||
| 2025-05-27 08:01 |
Regulatory News Service
FDA Orphan Drug Designation granted for POLB 001
|
English | 18.0 KB | ||
| 2025-05-27 08:00 |
Report Publication Announcement
Annual Report, AGM Notice & Circular
|
English | 16.2 KB | ||
| 2025-05-23 08:00 |
Share Issue/Capital Change
Result of upsized oversubscribed BookBuild Offer
|
English | 26.8 KB | ||
| 2025-03-27 08:00 |
Regulatory News Service
Conference Participation in March & April 2025
|
English | 15.6 KB | ||
| 2025-02-21 08:00 |
M&A Activity
Termination of proposed combination with HOOKIPA
|
English | 16.2 KB | ||
| 2025-02-18 18:35 |
Major Shareholding Notification
Holding(s) in Company
|
English | 43.7 KB | ||
| 2025-02-18 18:04 |
Major Shareholding Notification
Form 8.3 - Poolbeg Pharma plc
|
English | 52.2 KB | ||
| 2025-01-30 08:00 |
Regulatory News Service
Offer Update - Extension to PUSU Deadline
|
English | 27.9 KB | ||
| 2025-01-17 19:25 |
Major Shareholding Notification
Replacement - Form 8.3 - Poolbeg Pharma plc
|
English | 52.6 KB | ||
| 2025-01-17 12:27 |
Major Shareholding Notification
Form 8.3 - Poolbeg Pharma plc
|
English | 51.3 KB | ||
| 2025-01-16 14:53 |
Major Shareholding Notification
Form 8.3 - Poolbeg Pharma plc
|
English | 52.2 KB | ||
| 2025-01-15 19:04 |
Major Shareholding Notification
Form 8.3 - Poolbeg Pharma plc
|
English | 52.1 KB |
Automate Your Workflow. Get a real-time feed of all POOLBEG PHARMA PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for POOLBEG PHARMA PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
